GRC 17536

Drug Profile

GRC 17536

Alternative Names: GRC 17536 potassium powder for inhalation - Glenmark Pharmaceuticals; GRC-17536

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antitussives
  • Mechanism of Action TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Neuropathic pain
  • Phase I/II Allergic asthma

Most Recent Events

  • 22 Aug 2016 Glenmark Pharmaceuticals files an IND application with the FDA in USA for conducting a phase IIb trial in Neuropathic pain (Glenmark Pharmaceuticals website) before August 2016
  • 16 Aug 2016 Glenmark Pharmaceuticals completes a phase I drug-drug interaction trial in Healthy volunteers in India (PO) before August 2016 (CTRI2015-01-005417)
  • 25 Jun 2015 Phase-II development for Cough and phase-I/II development for Allergic asthma are ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top